Eli Lilly: to present results at ASH meeting

(CercleFinance.com) - Eli Lilly has announced that data from studies on Jaypirca® (pirtobrutinib), a non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK), will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), to be held December 7-10 in San Diego.


In an oral presentation, Lilly will present results from the phase 3 BRUIN CLL-321 study.

This study is evaluating pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) pretreated with a BTK inhibitor.

Copyright (c) 2024 CercleFinance.com. All rights reserved.